You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Skin conditions
  5. Psoriasis

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

  • Technology appraisal guidance
  • Reference number: TA455
  • Published:  12 July 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Research recommendations coming out of this guidance

  • Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

Back to top